Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses a prescribed hair loss treatment combining 12.5% minoxidil with tretinoin, azelaic acid, and topical finasteride, costing $55 a month. One user criticizes the packaging for degrading tretinoin, another suggests it's an overpriced option and recommends topical dutasteride as an alternative due to its higher molecular weight and lower systemic absorption.

A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.

PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.

Hair loss discussion includes PRP procedures. Some say it's not worth the money.

The conversation is about the availability of the PP405 formula for hair loss treatment, with mentions of finasteride and its side effects. Users discuss the potential of obtaining the formula through unofficial channels and the challenges related to its genetic sequence and delivery method.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

The user is seeking cheaper options for finasteride and minoxidil in Canada, as their current treatment costs nearly $100 monthly. They mention insurance doesn't cover finasteride and face prescription limitations.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

Pyrilutamide is being discussed as an alternative for those who can't use finasteride, but users report it may be ineffective at low concentrations. Some users are combining it with minoxidil, microneedling, and other treatments, but results vary.

PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."

The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.

The conversation discusses purchasing Avodart (dutasteride) at a low price, with the OP using 1mg daily for hair loss. Users inquire about the source, and OP confirms buying from Oxford Pharmacy in the UK.

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

You can get dutasteride in Germany through the Teleclinic app, which sends a prescription to a nearby pharmacy. It costs around 18-19 euros for the prescription and 47 euros for 90 pills of Avodart 0.5.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

People are discussing Breezula, a hair loss treatment, with mixed opinions on its value for the cost. Some are interested in it, while others think it's not worth the money.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Hair transplants cost more in the U.S. than in Turkey, but quality varies. Proper research is essential, as aggressive transplants can exhaust donor hair, and finasteride only slows hair loss.

Finasteride can be purchased at competitive prices from Costco, Amazon, and Cost Plus Drugs, with GoodRx offering local deals. Splitting 5mg tablets may reduce costs if approved by a doctor.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

Lactic acid is not effective for hair growth when applied topically. JXL069, finasteride, and minoxidil are suggested as alternative treatments.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.